- Mitsubishi Chemical Group (Jersey City, NJ)
- …difficult-to-treat diseases and commercializing products with significant unmet medical needs in North American markets. In the United States, MTPA launched rare ... and RADICAVA(R) (edaravone) oral suspension in 2022. The company handles research, clinical development , sales, marketing, medical affairs, and business … more
- Mitsubishi Chemical Group (Jersey City, NJ)
- …difficult-to-treat diseases and commercializing products with significant unmet medical needs in North American markets. In the United States, MTPA launched rare ... and RADICAVA(R) (edaravone) oral suspension in 2022. The company handles research, clinical development , sales, marketing, medical affairs, and business … more
- Mitsubishi Chemical Group (Jersey City, NJ)
- …difficult-to-treat diseases and commercializing products with significant unmet medical needs in North American markets. In the United States, MTPA launched rare ... and RADICAVA(R) (edaravone) oral suspension in 2022. The company handles research, clinical development , sales, marketing, medical affairs, and business … more
- Mitsubishi Chemical Group (Jersey City, NJ)
- …difficult-to-treat diseases and commercializing products with significant unmet medical needs in North American markets. In the United States, MTPA launched rare ... and RADICAVA(R) (edaravone) oral suspension in 2022. The company handles research, clinical development , sales, marketing, medical affairs, and business … more
- Mitsubishi Chemical Group (Jersey City, NJ)
- …difficult-to-treat diseases and commercializing products with significant unmet medical needs in North American markets. In the United States, MTPA launched rare ... and RADICAVA(R) (edaravone) oral suspension in 2022. The company handles research, clinical development , sales, marketing, medical affairs, and business … more
- Mitsubishi Chemical Group (Jersey City, NJ)
- …difficult-to-treat diseases and commercializing products with significant unmet medical needs in North American markets. In the United States, MTPA launched rare ... and RADICAVA(R) (edaravone) oral suspension in 2022. The company handles research, clinical development , sales, marketing, medical affairs, and business … more
- Mitsubishi Chemical Group (Jersey City, NJ)
- …difficult-to-treat diseases and commercializing products with significant unmet medical needs in North American markets. In the United States, MTPA launched rare ... and RADICAVA(R) (edaravone) oral suspension in 2022. The company handles research, clinical development , sales, marketing, medical affairs, and business … more
- Sanofi Group (Trenton, NJ)
- …and Regional Account Lead, and is a member of the Sanofi Speciality Care North American Medical team. Territory: Upper Northeast; US **Job Roles and ... safe and appropriate use of Sanofi therapies. The MVO assists in the development of Integrated Medical Plans through collaboration with Medical therapeutic areas and… more
- Mitsubishi Chemical Group (Jersey City, NJ)
- …difficult-to-treat diseases and commercializing products with significant unmet medical needs in North American markets. In the United States, MTPA launched rare ... and RADICAVA(R) (edaravone) oral suspension in 2022. The company handles research, clinical development , sales, marketing, medical affairs, and business … more
- Mitsubishi Chemical Group (Jersey City, NJ)
- …difficult-to-treat diseases and commercializing products with significant unmet medical needs in North American markets. In the United States, MTPA launched rare ... and RADICAVA(R) (edaravone) oral suspension in 2022. The company handles research, clinical development , sales, marketing, medical affairs, and business … more
- Mitsubishi Chemical Group (Jersey City, NJ)
- …difficult-to-treat diseases and commercializing products with significant unmet medical needs in North American markets. In the United States, MTPA launched rare ... and RADICAVA(R) (edaravone) oral suspension in 2022. The company handles research, clinical development , sales, marketing, medical affairs, and business … more
- Mitsubishi Chemical Group (Jersey City, NJ)
- …difficult-to-treat diseases and commercializing products with significant unmet medical needs in North American markets. In the United States, MTPA launched rare ... and RADICAVA(R) (edaravone) oral suspension in 2022. The company handles research, clinical development , sales, marketing, medical affairs, and business … more
- Mitsubishi Chemical Group (Jersey City, NJ)
- …difficult-to-treat diseases and commercializing products with significant unmet medical needs in North American markets. In the United States, MTPA launched rare ... and RADICAVA(R) (edaravone) oral suspension in 2022. The company handles research, clinical development , sales, marketing, medical affairs, and business … more
- Mitsubishi Chemical Group (Jersey City, NJ)
- …difficult-to-treat diseases and commercializing products with significant unmet medical needs in North American markets. In the United States, MTPA launched rare ... and RADICAVA(R) (edaravone) oral suspension in 2022. The company handles research, clinical development , sales, marketing, medical affairs, and business … more
- Mitsubishi Chemical Group (Princeton, NJ)
- …difficult-to-treat diseases and commercializing products with significant unmet medical needs in North American markets. In the United States, MTPA launched rare ... and RADICAVA(R) (edaravone) oral suspension in 2022. The company handles research, clinical development , sales, marketing, medical affairs, and business … more
- Mitsubishi Chemical Group (Jersey City, NJ)
- …difficult-to-treat diseases and commercializing products with significant unmet medical needs in North American markets. In the United States, MTPA launched rare ... and RADICAVA(R) (edaravone) oral suspension in 2022. The company handles research, clinical development , sales, marketing, medical affairs, and business … more
- Mitsubishi Chemical Group (Jersey City, NJ)
- …difficult-to-treat diseases and commercializing products with significant unmet medical needs in North American markets. In the United States, MTPA launched rare ... and RADICAVA(R) (edaravone) oral suspension in 2022. The company handles research, clinical development , sales, marketing, medical affairs, and business … more
- Mitsubishi Chemical Group (Jersey City, NJ)
- …difficult-to-treat diseases and commercializing products with significant unmet medical needs in North American markets. In the United States, MTPA launched rare ... and RADICAVA(R) (edaravone) oral suspension in 2022. The company handles research, clinical development , sales, marketing, medical affairs, and business … more
- Mitsubishi Chemical Group (Jersey City, NJ)
- …difficult-to-treat diseases and commercializing products with significant unmet medical needs in North American markets. In the United States, MTPA launched rare ... and RADICAVA(R) (edaravone) oral suspension in 2022. The company handles research, clinical development , sales, marketing, medical affairs, and business … more
- Mitsubishi Chemical Group (Jersey City, NJ)
- …difficult-to-treat diseases and commercializing products with significant unmet medical needs in North American markets. In the United States, MTPA launched rare ... and RADICAVA(R) (edaravone) oral suspension in 2022. The company handles research, clinical development , sales, marketing, medical affairs, and business … more